Teresa T Cabrera

List of Publications by Year
in descending order

69 papers	5,035 citations	117571 34 h-index	114418 63 g-index
71 all docs	71 docs citations	71 times ranked	4501 citing authors

#	Article	IF	Citations
1	Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis. Journal of Oncology, 2021, 2021, 1-9.	0.6	4
2	HLA-DRB1 âˆ— 16:01 and HLA-DQB1 âˆ— 05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma. Journal of Oncology, 2021, 2021, 1-7.	0.6	3
3	Cytotoxic effects of alkaline tetrasodium EDTA irrigating solutions. Journal of Oral Science, 2020, 62, 285-287.	0.7	5
4	Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. Cancer Immunology, Immunotherapy, 2016, 65, 47-59.	2.0	35
5	HLA Class I Expression in Human Cancer. , 2013, , 13-30.		0
6	MHC Class I Antigens In Malignant Cells. , 2013, , .		3
7	A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum thiol oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis. Molecular and Cellular Proteomics, 2013, 12, 2111-2125.	2.5	32
8	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0
9	Overview of MHC Class I Antigens. , 2013, , 1-11.		0
10	Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonâ€mediated rejection genes. International Journal of Cancer, 2012, 131, 387-395.	2.3	75
11	Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunology, Immunotherapy, 2011, 60, 869-882.	2.0	19
12	Frequent loss of heterozygosity in the Î²2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics, 2011, 63, 65-71.	1.2	75
13	Bacillus Calmetteâ€Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class Iâ€deficient tumor cells. International Journal of Cancer, 2011, 129, 839-846.	2.3	52
14	Analysis of HLAâ€“ABC locus-specific transcription in normal tissues. Immunogenetics, 2010, 62, 711-719.	1.2	33
15	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 2010, 127, 249-256.	2.3	232
16	Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens, 2010, 75, 110-118.	1.0	21
17	â€œHardâ€•and â€œsoftâ€•lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. , 2010, 127, 249.		1
18	HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunology, Immunotherapy, 2009, 58, 1507-1515.	2.0	53

#	Article	IF	Citations
19	Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 2008, 60, 439-447.	1.2	119
20	Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunology, Immunotherapy, 2008, 57, 1727-1733.	2.0	56
21	HLA Class I Expression, Tumor Escape and Cancer Progression. Current Cancer Therapy Reviews, 2008, 4, 105-110.	0.2	3
22	Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131.	0.8	117
23	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
24	Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens, 2007, 69, 264-268.	1.0	26
25	Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. Tissue Antigens, 2007, 69, 220-226.	1.0	31
26	HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunology, Immunotherapy, 2007, 56, 709-717.	2.0	78
27	Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens, 2006, 68, 303-310.	1.0	35
28	LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas. Immunogenetics, 2006, 58, 503-510.	1.2	56
29	Coordinated downregulation of the antigen presentation machinery and HLA class I/Î²2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 2005, 113, 605-610.	2.3	116
30	Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunology, Immunotherapy, 2005, 54, 400-406.	2.0	88
31	Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 858-866.	2.0	62
32	The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10.	2.0	239
33	Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics, 2004, 56, 244-53.	1.2	77
34	Analysis of HLA expression in human tumor tissues. Cancer Immunology, Immunotherapy, 2003, 52, 1-9.	2.0	98
35	Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Î²2 -microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens, 2003, 61, 211-219.	1.0	134
36	HLA class I expression in bladder carcinomas. Tissue Antigens, 2003, 62, 324-327.	1.0	30

#	Article	IF	Citations
37	High frequency of HLA-B44 allelic losses in human solid tumors. Human Immunology, 2003, 64, 941-950.	1.2	26
38	Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology, Immunotherapy, 2002, 51, 389-396.	2.0	105
39	HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology, 2002, 12, 3-13.	4.3	233
40	Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Seminars in Cancer Biology, 2002, 12, 15-24.	4.3	31
41	A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics, 2001, 53, 606-610.	1.2	29
42	Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. Cancer Immunology, Immunotherapy, 2000, 48, 684-690.	2.0	21
43	? 2 -microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. International Journal of Clinical and Laboratory Research, 2000, 30, 87-92.	1.0	13
44	High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Human Immunology, 2000, 61, 499-506.	1.2	43
45	Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Human Immunology, 2000, 61, 1001-1012.	1.2	58
46	The HLA crossroad in tumor immunology. Human Immunology, 2000, 61, 65-73.	1.2	129
47	Looking for HLA-G expression in human tumours. Journal of Reproductive Immunology, 1999, 43, 263-273.	0.8	13
48	Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518.		65
49	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97.		104
50	Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. International Journal of Cancer, 1999, 83, 91-97.	2.3	3
51	High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens, 1998, 52, 114-123.	1.0	84
52	Mutations of the Î²₂â€microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 1998, 52, 520-529.	1.0	132
53	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95.	7.5	708
54	High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 1996, 50, 127-134.	1.2	126

#	Article	IF	Citations
55	Characterization of a gastric tumor cell line defective in MHC class I inducibility by both Î±â€•and Î³â€‐interferon. Tissue Antigens, 1996, 47, 391-398.	1.0	45
56	Biological Implications of HLA-DR Expression in Tumours. Scandinavian Journal of Immunology, 1995, 41, 398-406.	1.3	52
57	Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195.	1.9	121
58	Upmodulation by estrogen of HLA class I expression in breast tumor cell lines. Human Immunology, 1994, 39, 129.	1.2	0
59	Natural history of HLA expression during tumour development. Trends in Immunology, 1993, 14, 491-499.	7.5	432
60	HLA class I expression and HPVâ€‐16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens, 1993, 41, 65-71.	1.0	46
61	HLA molecules in basal cell carcinoma of the skin. Immunobiology, 1992, 185, 440-452.	0.8	25
62	HLA Class I and II Expression in Rhabdomyosarcomas. Immunobiology, 1991, 182, 440-448.	0.8	18
63	Loss of HLA Heavy Chain and beta2-Microglobulin in HLA Negative Tumours. Scandinavian Journal of Immunology, 1991, 34, 147-152.	1.3	17
64	Molecular analysis of MHC-class-I alterations in human tumor cell lines. International Journal of Cancer, 1991, 47, 123-130.	2.3	25
65	Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. International Journal of Cancer, 1991, 47, 146-154.	2.3	50
66	Presence of hpv 16 sequences in laryngeal carcinomas. International Journal of Cancer, 1990, 46, 8-11.	2.3	97
67	K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. International Journal of Cancer, 1990, 46, 426-431.	2.3	17
68	Class II HLA Antigen Expression in Familial Polyposis Coli is Related to the Degree of Dysplasia. Immunobiology, 1990, 180, 138-148.	0.8	11
69	A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. Hybridoma, 1985, 4, 369-378.	0.9	9